ENDO PHARMACEUTICALS REPORTS SALES UP 61% FOR SECOND
QUARTER.(Brief Article)(Statistical Data Included)
Endo Pharmaceuticals Holdings Inc. (Nasdaq: ENDP; ENDPW), Chadds
Ford, Pa., a fully integrated pharmaceutical company with market
leadership in pain management, has reported its financial results . . .
CYANOTECH REPORTS 35% INCREASE IN FIRST QTR.SALES FISCAL
2001.(Brief Article)(Statistical Data Included)
Cyanotech Corporation (Nasdaq NMS:CYAN), Kailua-Kona, Hawaii, a
leader in producing high-value, natural products from microalgae, has
announced financial results for the first quarter of fiscal . . .
TWINLAB REPORTS NET SALES DOWN IN SECOND QUARTER.(Brief
Article)(Statistical Data Included)
Twinlab Corporation (NASDAQ: TWLB), Hauppauge, N.Y., has announced
its results for the second quarter and six months ended June 30, 2000.
For the second quarter of 2000, net sales were $60.1, . . .
CARDIAC SCIENCE 2ND. QTR. REVENUE UP 48%.(Brief
Article)(Statistical Data Included)
Cardiac Science Inc. (OTCBB: DFIB), Irvine, Calif., the developer
of the only hospital monitor to provide life-saving defibrillation
within seconds and without the aid of hospital staff, has . . .
ICON REPORTS LVC PROCEDURE GROWTH RATE UP 270% YR-TO-YR.(Brief
Article)(Statistical Data Included)
ICON Laser Eye Centers, Inc. (CDN:ILEcu.)(OTC CDN: ILEC.U-
Canadian Dealers Network) ("ICON"), Toronto, a leading
international laser vision correction ("LVC") provider has
announced that 23,491 . . .
ILLUMINA REPORTS NET LOSS OF $5.3 MILLION FOR 2ND. QUARTER.(Brief
Article)(Statistical Data Included)
For the quarter ended June 30, 2000, Illumina, Inc., San Diego,
has reported a net loss of $5.3 million, or $0.25 per share on a pro
forma basis, compared to a net loss of $1.1 million, or $0.09 . . .
TWINLAB REPORTS NET SALES DOWN IN SECOND QUARTER.(Brief
Article)(Statistical Data Included)
Twinlab Corporation (NASDAQ: TWLB), Hauppauge, N.Y., has announced
its results for the second quarter and six months ended June 30, 2000.
For the second quarter of 2000, net sales were $60.1, . . .
MATRIX REPORTS NET LOSS FOR SECOND QUARTER.(Brief
Article)(Statistical Data Included)
Matrix Pharmaceutical, Inc. (Nasdaq:MATX), Fremont, Calif., has
reported financial results for the three months ended June 30, 2000.
Matrix reported a net loss for the second quarter of 2000 . . .
INTERMUNE'S 2ND. QTR. ACTIMMUNE SALES INCREASE BY
178%.(Brief Article)(Statistical Data Included)
InterMune Pharmaceuticals (Nasdaq: ITMN), Burlingame, Calif., has
announced financial results for the second quarter, ended June 30, 2000.
InterMune reported a net loss of $6.9 million, or $0.33 . . .
DRAXIS DIVESTS TIAMOL/KERASAL PRODUCT LINES TO TARO.(Brief
Article)(Statistical Data Included)
DRAXIS Health Inc. (TSE:DAX.) (NASDAQ: DRAX), Mississauga,
Ontario, has entered into an agreement to dispose of its Tiamol(R) and
Kerasal(R) dermatological product lines to Taro . . .
MATRIX REPORTS NET LOSS FOR SECOND QUARTER.(Brief
Article)(Statistical Data Included)
Matrix Pharmaceutical, Inc. (Nasdaq:MATX), Fremont, Calif., has
reported financial results for the three months ended June 30, 2000.
Matrix reported a net loss for the second quarter of 2000 . . .
INTERMUNE'S 2ND. QTR. ACTIMMUNE SALES INCREASE BY
178%.(Brief Article)(Statistical Data Included)
InterMune Pharmaceuticals (Nasdaq: ITMN), Burlingame, Calif., has
announced financial results for the second quarter, ended June 30, 2000.
InterMune reported a net loss of $6.9 million, or $0.33 . . .
COLLAGENEX REPORTS 2ND. QTR. NET REVENUES OF $6.7 MILLION.(Brief
Article)(Statistical Data Included)
CollaGenex Pharmaceuticals, Inc. (Nasdaq: CGPI), Newtown, Pa.,
has announced net revenues of $6.7 million in the second quarter of 2000
compared to $3.4 million in the second quarter of 1999.
. . .
BIOGEN REPORTS AVONEX SALES UP 30% FOR SAME QTR. 1999.(Brief
Article)(Statistical Data Included)
Biogen, Inc. (NASDAQ/BGEN), Cambridge, Mass., has reported
financial results for the second quarter of 2000. For the three months
ended June 30, 2000, the company reported net income of . . .
SYNSORB BIOTECH REPORTS NET INCOME OF $137,000 FOR FIRST
QTR.
SYNSORB Biotech Inc. ("SYNSORB") (TSE:SYB, NASDAQ:SYBB),
Calgary, Alberta, has reported net income for the quarter ended March
31, 2000 of $137,000 or $0.004 per share compared to a loss . . .
LUXTEC REPORTS 3RD. SUCCESSIVE PROFITABLE QTR.(Brief
Article)(Statistical Data Included)
Luxtec Corporation (AMEX:LXU), Worcester, Mass., has reported
continued improvement in earnings in the third fiscal quarter ended July
31, 2000.
The company, the world's leading supplier of . . .
COLLAGENEX REPORTS 2ND. QTR. NET REVENUES OF $6.7 MILLION.(Brief
Article)(Statistical Data Included)
CollaGenex Pharmaceuticals, Inc. (Nasdaq: CGPI), Newtown, Pa.,
has announced net revenues of $6.7 million in the second quarter of 2000
compared to $3.4 million in the second quarter of 1999.
. . .
CYANOTECH REPORTS 35% INCREASE IN FIRST QTR.SALES FISCAL
2001.(Brief Article)(Statistical Data Included)
Cyanotech Corporation (Nasdaq NMS:CYAN), Kailua-Kona, Hawaii, a
leader in producing high-value, natural products from microalgae, has
announced financial results for the first quarter of fiscal . . .
OSTEX REPORTS 39% INCREASE IN 2ND. QTR. REVENUES OVER 1999.(Brief
Article)(Statistical Data Included)
Ostex International, Inc. (Nasdaq:OSTX), Seattle, has announced
results of operations for the second quarter and the first six months of
2000.
Total revenues for the second quarter were . . .
IMMTECH REPORTS NET LOSS FOR 4TH QTR. AND FISCAL 2000.(Brief
Article)(Statistical Data Included)
Immtech International Inc. (NASDAQ NMS:IMMT), Vernon Hills, Ill.,
a biopharmaceutical company focused on the delivery and
commercialization of drugs for the treatment of fungal diseases, . . .
|
|